Journal of Clinical Oncology
Articles in this Issue
How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability
Reply to: “Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases,” “Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,” and “Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases”
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...
Good Oncologist: Doctoring Lessons From the Art of Oncology
Qualitative analysis of narrative essays authored by cancer care professionals offer insights into what it means to be a “good oncologist.”
When the System Is the Treatment: Rethinking Nonpharmacologic Breakthroughs in Oncology
Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer
PURPOSE The CALYPSO study demonstrated activity of savolitinib and durvalumab in MET -driven papillary renal canc...
Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer
Randomized trials provide evidence for regulatory and clinical decision making in oncology. However, trials cannot answer every important clinical question. Evidence gaps often persist in under-repres...
Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer
Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials
Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening
PURPOSE This study investigates the relationship between prediagnosis financial hardship (FH) and cancer stage, and the mediating role of cancer screening in breast cancer....
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
PURPOSE Immune checkpoint inhibitors (ICIs) achieve sufficient receptor occupancy at much lower than standard approved doses. We hypothesized that ultra-low-dose nivolumab would re...
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
PURPOSE There is no standard second-line therapy for gastroenteropancreatic (GEP) and lung large-cell neuroendocrine carcinoma (NEC) after the failure of platinum-based chemotherap...
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
PURPOSE The PD-1 inhibitor pembrolizumab is approved as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In L...
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
PURPOSE Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in ea...